msgpackr 1.5.3 → 1.5.6
This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
- package/README.md +2 -1
- package/dist/index.js +38 -33
- package/dist/index.min.js +63 -62
- package/dist/node.cjs +39 -35
- package/dist/test.js +5 -580
- package/node-index.js +1 -2
- package/pack.js +30 -32
- package/package.json +2 -2
- package/unpack.d.ts +2 -0
- package/unpack.js +8 -1
package/dist/test.js
CHANGED
|
@@ -1,586 +1,9 @@
|
|
|
1
|
-
(function (msgpackr, chai) {
|
|
1
|
+
(function (msgpackr, chai, fs) {
|
|
2
2
|
'use strict';
|
|
3
3
|
|
|
4
4
|
chai = chai && Object.prototype.hasOwnProperty.call(chai, 'default') ? chai['default'] : chai;
|
|
5
5
|
|
|
6
|
-
|
|
7
|
-
Designs: [
|
|
8
|
-
"Randomized Controlled Trial"
|
|
9
|
-
],
|
|
10
|
-
Types: [
|
|
11
|
-
],
|
|
12
|
-
BriefSummary: "To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4\n weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The\n dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a\n calibrator.",
|
|
13
|
-
Abstract: "To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4\n weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The\n dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a\n calibrator.",
|
|
14
|
-
Acronym: null,
|
|
15
|
-
ArticleId: "Qy3gwKWSoaWRmbmFEQA",
|
|
16
|
-
Authors: null,
|
|
17
|
-
CochraneID: null,
|
|
18
|
-
Confidential: false,
|
|
19
|
-
CorporateAuthor: null,
|
|
20
|
-
Country: "Bulgaria, Canada, Hungary, Israel, Norway, Slovakia, United Kingdom, United States",
|
|
21
|
-
CustomData: null,
|
|
22
|
-
DatabaseType: "ClinicalTrials.gov",
|
|
23
|
-
DOI: null,
|
|
24
|
-
EmbaseAccessionNumber: null,
|
|
25
|
-
Emtree: null,
|
|
26
|
-
ErrataText: null,
|
|
27
|
-
FullTextURL: null,
|
|
28
|
-
Institution: null,
|
|
29
|
-
ISSN: null,
|
|
30
|
-
Issue: null,
|
|
31
|
-
JournalTitle: null,
|
|
32
|
-
MedlineID: null,
|
|
33
|
-
MeSH: "Hypercholesterolemia|Antibodies, Monoclonal",
|
|
34
|
-
Pages: null,
|
|
35
|
-
ParentChildStatus: null,
|
|
36
|
-
ParentID: null,
|
|
37
|
-
PublicationDate: "March 21, 2017",
|
|
38
|
-
PublicationYear: 2017,
|
|
39
|
-
PubType: null,
|
|
40
|
-
ReferenceStudy: null,
|
|
41
|
-
SecondarySourceID: null,
|
|
42
|
-
Source: "Regeneron Pharmaceuticals",
|
|
43
|
-
SourceReferenceId: "NCT01926782",
|
|
44
|
-
TaStudyDesign: "Randomized",
|
|
45
|
-
Title: "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",
|
|
46
|
-
TrialOutcome: null,
|
|
47
|
-
Volume: null,
|
|
48
|
-
Id: 179246831,
|
|
49
|
-
Created: "2020-04-10T14:48:20.4384957Z",
|
|
50
|
-
VersionNo: 2,
|
|
51
|
-
ExtractData: null,
|
|
52
|
-
Digitized: true,
|
|
53
|
-
IsRapidExtract: false,
|
|
54
|
-
IsUploaded: false
|
|
55
|
-
};
|
|
56
|
-
var design = "Randomized Controlled Trial";
|
|
57
|
-
var conditions = [
|
|
58
|
-
{
|
|
59
|
-
label: "Cholesterol Total Increased",
|
|
60
|
-
id: "SUE_c"
|
|
61
|
-
}
|
|
62
|
-
];
|
|
63
|
-
var phase = 3;
|
|
64
|
-
var name = "NCT01926782";
|
|
65
|
-
var trialIds = [
|
|
66
|
-
"NCT01926782"
|
|
67
|
-
];
|
|
68
|
-
var acronyms = [
|
|
69
|
-
];
|
|
70
|
-
var outcomeCount = 156;
|
|
71
|
-
var id = 179246831;
|
|
72
|
-
var groups = [
|
|
73
|
-
{
|
|
74
|
-
Id: "4r",
|
|
75
|
-
RefId: "B5|O2~Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin",
|
|
76
|
-
OriginalName: "Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin",
|
|
77
|
-
N: 37,
|
|
78
|
-
age: 59.3,
|
|
79
|
-
ageSD: 11.3,
|
|
80
|
-
male: 37.83783783783784,
|
|
81
|
-
Interventions: [
|
|
82
|
-
{
|
|
83
|
-
termIds: [
|
|
84
|
-
[
|
|
85
|
-
"SUBYEL",
|
|
86
|
-
"SUB_Oc"
|
|
87
|
-
],
|
|
88
|
-
[
|
|
89
|
-
"SUNUVb"
|
|
90
|
-
]
|
|
91
|
-
]
|
|
92
|
-
}
|
|
93
|
-
],
|
|
94
|
-
analyzeAs: "Alirocumab",
|
|
95
|
-
analyzableScore: 1.0717734625362931,
|
|
96
|
-
matchingScore: 0
|
|
97
|
-
},
|
|
98
|
-
{
|
|
99
|
-
Id: "zB",
|
|
100
|
-
RefId: "B6|O3~Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin",
|
|
101
|
-
OriginalName: "Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin",
|
|
102
|
-
N: 146,
|
|
103
|
-
age: 59.2,
|
|
104
|
-
ageSD: 10.8,
|
|
105
|
-
male: 45.205479452054796,
|
|
106
|
-
Interventions: [
|
|
107
|
-
{
|
|
108
|
-
termIds: [
|
|
109
|
-
[
|
|
110
|
-
"SUBYEL",
|
|
111
|
-
"SUB_Oc"
|
|
112
|
-
]
|
|
113
|
-
]
|
|
114
|
-
}
|
|
115
|
-
],
|
|
116
|
-
analyzeAs: "Statins",
|
|
117
|
-
analyzableScore: 1.0717734625362931,
|
|
118
|
-
matchingScore: 0
|
|
119
|
-
},
|
|
120
|
-
{
|
|
121
|
-
Id: "3!",
|
|
122
|
-
RefId: "B4|O1~Placebo Q2W Without Concomitant Statin",
|
|
123
|
-
OriginalName: "Placebo Q2W Without Concomitant Statin",
|
|
124
|
-
N: 73,
|
|
125
|
-
age: 59.4,
|
|
126
|
-
ageSD: 10.2,
|
|
127
|
-
male: 54.794520547945204,
|
|
128
|
-
Interventions: [
|
|
129
|
-
{
|
|
130
|
-
termIds: [
|
|
131
|
-
[
|
|
132
|
-
"SUGeLS"
|
|
133
|
-
],
|
|
134
|
-
[
|
|
135
|
-
"SUBYEL",
|
|
136
|
-
"SUB_Oc"
|
|
137
|
-
]
|
|
138
|
-
]
|
|
139
|
-
}
|
|
140
|
-
],
|
|
141
|
-
analyzeAs: "Control",
|
|
142
|
-
analyzableScore: 1.2020833333333334,
|
|
143
|
-
matchingScore: 0
|
|
144
|
-
},
|
|
145
|
-
{
|
|
146
|
-
Id: "tv",
|
|
147
|
-
RefId: "E3",
|
|
148
|
-
OriginalName: "Alirocumab 300 mg Q4W/Up 150 mg Q2W",
|
|
149
|
-
Interventions: [
|
|
150
|
-
{
|
|
151
|
-
termIds: [
|
|
152
|
-
[
|
|
153
|
-
"SUCO54",
|
|
154
|
-
"SUNUVb"
|
|
155
|
-
]
|
|
156
|
-
]
|
|
157
|
-
}
|
|
158
|
-
]
|
|
159
|
-
},
|
|
160
|
-
{
|
|
161
|
-
Id: "jt",
|
|
162
|
-
RefId: "B3|O3~Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin",
|
|
163
|
-
OriginalName: "Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin",
|
|
164
|
-
N: 312,
|
|
165
|
-
age: 61.6,
|
|
166
|
-
ageSD: 10,
|
|
167
|
-
male: 60.8974358974359,
|
|
168
|
-
Interventions: [
|
|
169
|
-
{
|
|
170
|
-
termIds: [
|
|
171
|
-
[
|
|
172
|
-
"SUBYEL",
|
|
173
|
-
"SUB_Oc"
|
|
174
|
-
]
|
|
175
|
-
]
|
|
176
|
-
}
|
|
177
|
-
]
|
|
178
|
-
},
|
|
179
|
-
{
|
|
180
|
-
Id: "5!",
|
|
181
|
-
RefId: "E2",
|
|
182
|
-
OriginalName: "Alirocumab 75 mg Q2W/Up 150 mg Q2W",
|
|
183
|
-
Interventions: [
|
|
184
|
-
{
|
|
185
|
-
termIds: [
|
|
186
|
-
[
|
|
187
|
-
"SUNUVb"
|
|
188
|
-
]
|
|
189
|
-
]
|
|
190
|
-
}
|
|
191
|
-
]
|
|
192
|
-
},
|
|
193
|
-
{
|
|
194
|
-
Id: "4E",
|
|
195
|
-
RefId: "B2|O2~Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin",
|
|
196
|
-
OriginalName: "Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin",
|
|
197
|
-
N: 78,
|
|
198
|
-
age: 60.7,
|
|
199
|
-
ageSD: 9.1,
|
|
200
|
-
male: 65.38461538461539,
|
|
201
|
-
Interventions: [
|
|
202
|
-
{
|
|
203
|
-
termIds: [
|
|
204
|
-
[
|
|
205
|
-
"SUBYEL",
|
|
206
|
-
"SUB_Oc"
|
|
207
|
-
],
|
|
208
|
-
[
|
|
209
|
-
"SUNUVb"
|
|
210
|
-
]
|
|
211
|
-
]
|
|
212
|
-
}
|
|
213
|
-
]
|
|
214
|
-
},
|
|
215
|
-
{
|
|
216
|
-
Id: "i4",
|
|
217
|
-
Interventions: [
|
|
218
|
-
{
|
|
219
|
-
Id: "Ya",
|
|
220
|
-
Name: 178613599,
|
|
221
|
-
Treatments: [
|
|
222
|
-
{
|
|
223
|
-
Id: "((",
|
|
224
|
-
Phase: "k)"
|
|
225
|
-
}
|
|
226
|
-
],
|
|
227
|
-
Type: "Drug",
|
|
228
|
-
termIds: [
|
|
229
|
-
[
|
|
230
|
-
"SUGeLS"
|
|
231
|
-
],
|
|
232
|
-
[
|
|
233
|
-
"SUNUVb"
|
|
234
|
-
]
|
|
235
|
-
],
|
|
236
|
-
terms: [
|
|
237
|
-
[
|
|
238
|
-
"Placebo"
|
|
239
|
-
],
|
|
240
|
-
[
|
|
241
|
-
"Alirocumab"
|
|
242
|
-
]
|
|
243
|
-
]
|
|
244
|
-
},
|
|
245
|
-
{
|
|
246
|
-
Id: "o)",
|
|
247
|
-
Name: 2159990,
|
|
248
|
-
Treatments: [
|
|
249
|
-
{
|
|
250
|
-
Id: "1$",
|
|
251
|
-
Phase: "k)"
|
|
252
|
-
}
|
|
253
|
-
],
|
|
254
|
-
Type: "Drug",
|
|
255
|
-
termIds: [
|
|
256
|
-
[
|
|
257
|
-
"SUBYEL"
|
|
258
|
-
]
|
|
259
|
-
],
|
|
260
|
-
terms: [
|
|
261
|
-
[
|
|
262
|
-
"Statins"
|
|
263
|
-
]
|
|
264
|
-
]
|
|
265
|
-
}
|
|
266
|
-
],
|
|
267
|
-
RefId: "E1|Placebo Q2W",
|
|
268
|
-
OriginalName: "Placebo Q2W"
|
|
269
|
-
},
|
|
270
|
-
{
|
|
271
|
-
Id: "Ls",
|
|
272
|
-
RefId: "B1|O1~Placebo Q2W With Concomitant Statin",
|
|
273
|
-
OriginalName: "Placebo Q2W With Concomitant Statin",
|
|
274
|
-
N: 157,
|
|
275
|
-
age: 61.6,
|
|
276
|
-
ageSD: 9.7,
|
|
277
|
-
male: 64.3312101910828,
|
|
278
|
-
Interventions: [
|
|
279
|
-
{
|
|
280
|
-
termIds: [
|
|
281
|
-
[
|
|
282
|
-
"SUGeLS"
|
|
283
|
-
],
|
|
284
|
-
[
|
|
285
|
-
"SUBYEL",
|
|
286
|
-
"SUB_Oc"
|
|
287
|
-
]
|
|
288
|
-
]
|
|
289
|
-
}
|
|
290
|
-
]
|
|
291
|
-
}
|
|
292
|
-
];
|
|
293
|
-
var hasDocData = true;
|
|
294
|
-
var hasRapidExtract = false;
|
|
295
|
-
var N = 803;
|
|
296
|
-
var queryScore = 1.4868329805051381;
|
|
297
|
-
var matchingScore = 7.960635921410255;
|
|
298
|
-
var score = 22.084654254966498;
|
|
299
|
-
var outcomes = [
|
|
300
|
-
{
|
|
301
|
-
id: "179246387",
|
|
302
|
-
type: "Change",
|
|
303
|
-
unit: "%",
|
|
304
|
-
termIds: [
|
|
305
|
-
[
|
|
306
|
-
"SUF0R",
|
|
307
|
-
"SUBskP"
|
|
308
|
-
]
|
|
309
|
-
],
|
|
310
|
-
quantifiers: [
|
|
311
|
-
],
|
|
312
|
-
name: "Calculated LDL-C in Not Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
313
|
-
cells: [
|
|
314
|
-
{
|
|
315
|
-
number: -0.4,
|
|
316
|
-
unit: "%",
|
|
317
|
-
group: "3!",
|
|
318
|
-
varType: "se",
|
|
319
|
-
N: 70,
|
|
320
|
-
se: 2,
|
|
321
|
-
sd: 16.73
|
|
322
|
-
},
|
|
323
|
-
{
|
|
324
|
-
number: -54.6,
|
|
325
|
-
unit: "%",
|
|
326
|
-
group: "4r",
|
|
327
|
-
varType: "se",
|
|
328
|
-
N: 37,
|
|
329
|
-
se: 2.8,
|
|
330
|
-
sd: 17.03
|
|
331
|
-
},
|
|
332
|
-
{
|
|
333
|
-
number: -59.4,
|
|
334
|
-
unit: "%",
|
|
335
|
-
group: "zB",
|
|
336
|
-
varType: "se",
|
|
337
|
-
N: 141,
|
|
338
|
-
se: 1.4,
|
|
339
|
-
sd: 16.62
|
|
340
|
-
}
|
|
341
|
-
],
|
|
342
|
-
time: {
|
|
343
|
-
Id: 67122072,
|
|
344
|
-
Low: {
|
|
345
|
-
Value: "Baseline"
|
|
346
|
-
},
|
|
347
|
-
High: {
|
|
348
|
-
"Number": 24,
|
|
349
|
-
Unit: "wk"
|
|
350
|
-
},
|
|
351
|
-
Type: "Total",
|
|
352
|
-
days: 168,
|
|
353
|
-
description: "24wk"
|
|
354
|
-
},
|
|
355
|
-
score: 2.08,
|
|
356
|
-
matchingTerm: "SUF0R",
|
|
357
|
-
suggestedPositive: false,
|
|
358
|
-
sourceUnit: "%"
|
|
359
|
-
},
|
|
360
|
-
{
|
|
361
|
-
id: "179246389",
|
|
362
|
-
type: "Change",
|
|
363
|
-
unit: "%",
|
|
364
|
-
termIds: [
|
|
365
|
-
[
|
|
366
|
-
"SUF0R",
|
|
367
|
-
"SUBskP"
|
|
368
|
-
]
|
|
369
|
-
],
|
|
370
|
-
quantifiers: [
|
|
371
|
-
],
|
|
372
|
-
name: "Calculated LDL-C in Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
373
|
-
cells: [
|
|
374
|
-
{
|
|
375
|
-
number: -0.3,
|
|
376
|
-
unit: "%",
|
|
377
|
-
group: "Ls",
|
|
378
|
-
varType: "se",
|
|
379
|
-
N: 151,
|
|
380
|
-
se: 2.1,
|
|
381
|
-
sd: 25.81
|
|
382
|
-
},
|
|
383
|
-
{
|
|
384
|
-
number: -55.1,
|
|
385
|
-
unit: "%",
|
|
386
|
-
group: "4E",
|
|
387
|
-
varType: "se",
|
|
388
|
-
N: 75,
|
|
389
|
-
se: 3,
|
|
390
|
-
sd: 25.98
|
|
391
|
-
},
|
|
392
|
-
{
|
|
393
|
-
number: -62.3,
|
|
394
|
-
unit: "%",
|
|
395
|
-
group: "jt",
|
|
396
|
-
varType: "se",
|
|
397
|
-
N: 302,
|
|
398
|
-
se: 1.5,
|
|
399
|
-
sd: 26.07
|
|
400
|
-
}
|
|
401
|
-
],
|
|
402
|
-
time: {
|
|
403
|
-
Id: 67122072,
|
|
404
|
-
Low: {
|
|
405
|
-
Value: "Baseline"
|
|
406
|
-
},
|
|
407
|
-
High: {
|
|
408
|
-
"Number": 24,
|
|
409
|
-
Unit: "wk"
|
|
410
|
-
},
|
|
411
|
-
Type: "Total",
|
|
412
|
-
days: 168,
|
|
413
|
-
description: "24wk"
|
|
414
|
-
},
|
|
415
|
-
score: 2.08,
|
|
416
|
-
matchingTerm: "SUF0R",
|
|
417
|
-
suggestedPositive: false,
|
|
418
|
-
sourceUnit: "%"
|
|
419
|
-
},
|
|
420
|
-
{
|
|
421
|
-
id: "179246393",
|
|
422
|
-
type: "Change",
|
|
423
|
-
unit: "%",
|
|
424
|
-
termIds: [
|
|
425
|
-
[
|
|
426
|
-
"SUF0R",
|
|
427
|
-
"SUBskP"
|
|
428
|
-
]
|
|
429
|
-
],
|
|
430
|
-
quantifiers: [
|
|
431
|
-
],
|
|
432
|
-
name: "Calculated LDL-C in Not Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
433
|
-
cells: [
|
|
434
|
-
{
|
|
435
|
-
number: -0.5,
|
|
436
|
-
unit: "%",
|
|
437
|
-
group: "3!",
|
|
438
|
-
varType: "se",
|
|
439
|
-
N: 70,
|
|
440
|
-
se: 2,
|
|
441
|
-
sd: 16.73
|
|
442
|
-
},
|
|
443
|
-
{
|
|
444
|
-
number: -53.9,
|
|
445
|
-
unit: "%",
|
|
446
|
-
group: "4r",
|
|
447
|
-
varType: "se",
|
|
448
|
-
N: 37,
|
|
449
|
-
se: 2.7,
|
|
450
|
-
sd: 16.42
|
|
451
|
-
},
|
|
452
|
-
{
|
|
453
|
-
number: -60,
|
|
454
|
-
unit: "%",
|
|
455
|
-
group: "zB",
|
|
456
|
-
varType: "se",
|
|
457
|
-
N: 141,
|
|
458
|
-
se: 1.4,
|
|
459
|
-
sd: 16.62
|
|
460
|
-
}
|
|
461
|
-
],
|
|
462
|
-
time: {
|
|
463
|
-
Id: 67122069,
|
|
464
|
-
Low: {
|
|
465
|
-
Value: "Baseline"
|
|
466
|
-
},
|
|
467
|
-
High: {
|
|
468
|
-
"Number": 12,
|
|
469
|
-
Unit: "wk"
|
|
470
|
-
},
|
|
471
|
-
Type: "Total",
|
|
472
|
-
days: 84,
|
|
473
|
-
description: "12wk"
|
|
474
|
-
},
|
|
475
|
-
score: 2.08,
|
|
476
|
-
matchingTerm: "SUF0R",
|
|
477
|
-
suggestedPositive: false,
|
|
478
|
-
sourceUnit: "%"
|
|
479
|
-
},
|
|
480
|
-
{
|
|
481
|
-
id: "179246394",
|
|
482
|
-
type: "Change",
|
|
483
|
-
unit: "%",
|
|
484
|
-
termIds: [
|
|
485
|
-
[
|
|
486
|
-
"SUF0R",
|
|
487
|
-
"SUBskP"
|
|
488
|
-
]
|
|
489
|
-
],
|
|
490
|
-
quantifiers: [
|
|
491
|
-
],
|
|
492
|
-
name: "Calculated LDL-C in Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
493
|
-
cells: [
|
|
494
|
-
{
|
|
495
|
-
number: 1.4,
|
|
496
|
-
unit: "%",
|
|
497
|
-
group: "Ls",
|
|
498
|
-
varType: "se",
|
|
499
|
-
N: 151,
|
|
500
|
-
se: 1.9,
|
|
501
|
-
sd: 23.35
|
|
502
|
-
},
|
|
503
|
-
{
|
|
504
|
-
number: -47.3,
|
|
505
|
-
unit: "%",
|
|
506
|
-
group: "4E",
|
|
507
|
-
varType: "se",
|
|
508
|
-
N: 75,
|
|
509
|
-
se: 2.8,
|
|
510
|
-
sd: 24.25
|
|
511
|
-
},
|
|
512
|
-
{
|
|
513
|
-
number: -58,
|
|
514
|
-
unit: "%",
|
|
515
|
-
group: "jt",
|
|
516
|
-
varType: "se",
|
|
517
|
-
N: 302,
|
|
518
|
-
se: 1.4,
|
|
519
|
-
sd: 24.33
|
|
520
|
-
}
|
|
521
|
-
],
|
|
522
|
-
time: {
|
|
523
|
-
Id: 67122069,
|
|
524
|
-
Low: {
|
|
525
|
-
Value: "Baseline"
|
|
526
|
-
},
|
|
527
|
-
High: {
|
|
528
|
-
"Number": 12,
|
|
529
|
-
Unit: "wk"
|
|
530
|
-
},
|
|
531
|
-
Type: "Total",
|
|
532
|
-
days: 84,
|
|
533
|
-
description: "12wk"
|
|
534
|
-
},
|
|
535
|
-
score: 2.08,
|
|
536
|
-
matchingTerm: "SUF0R",
|
|
537
|
-
suggestedPositive: false,
|
|
538
|
-
sourceUnit: "%"
|
|
539
|
-
}
|
|
540
|
-
];
|
|
541
|
-
var characteristics = [
|
|
542
|
-
{
|
|
543
|
-
id: "179246354",
|
|
544
|
-
type: "Binary",
|
|
545
|
-
isCharacteristic: true,
|
|
546
|
-
termIds: [
|
|
547
|
-
[
|
|
548
|
-
"SUE_c",
|
|
549
|
-
"SUCbN",
|
|
550
|
-
"SUyJj"
|
|
551
|
-
]
|
|
552
|
-
],
|
|
553
|
-
quantifiers: [
|
|
554
|
-
],
|
|
555
|
-
name: "Patients not having adequate control of their hypercholesterolemia based on their individual level of CVD risk",
|
|
556
|
-
cells: [
|
|
557
|
-
],
|
|
558
|
-
number: 100
|
|
559
|
-
}
|
|
560
|
-
];
|
|
561
|
-
var outcomesScore = 18.97947630112307;
|
|
562
|
-
var sampleData = {
|
|
563
|
-
metadata: metadata,
|
|
564
|
-
design: design,
|
|
565
|
-
conditions: conditions,
|
|
566
|
-
phase: phase,
|
|
567
|
-
name: name,
|
|
568
|
-
trialIds: trialIds,
|
|
569
|
-
acronyms: acronyms,
|
|
570
|
-
outcomeCount: outcomeCount,
|
|
571
|
-
id: id,
|
|
572
|
-
groups: groups,
|
|
573
|
-
hasDocData: hasDocData,
|
|
574
|
-
hasRapidExtract: hasRapidExtract,
|
|
575
|
-
N: N,
|
|
576
|
-
queryScore: queryScore,
|
|
577
|
-
matchingScore: matchingScore,
|
|
578
|
-
score: score,
|
|
579
|
-
outcomes: outcomes,
|
|
580
|
-
characteristics: characteristics,
|
|
581
|
-
outcomesScore: outcomesScore
|
|
582
|
-
};
|
|
583
|
-
|
|
6
|
+
const sampleData = JSON.parse(fs.readFileSync(new URL('./example4.json', (document.currentScript && document.currentScript.src || new URL('test.js', document.baseURI).href))));
|
|
584
7
|
function tryRequire(module) {
|
|
585
8
|
try {
|
|
586
9
|
return require(module)
|
|
@@ -859,6 +282,7 @@
|
|
|
859
282
|
object.children[2] = object.children[0];
|
|
860
283
|
object.childrenAgain = object.children;
|
|
861
284
|
let packr = new Packr({
|
|
285
|
+
moreTypes: true,
|
|
862
286
|
structuredClone: true,
|
|
863
287
|
});
|
|
864
288
|
var serialized = packr.pack(object);
|
|
@@ -883,6 +307,7 @@
|
|
|
883
307
|
uint16Array: new Uint16Array([3,4])
|
|
884
308
|
};
|
|
885
309
|
let packr = new Packr({
|
|
310
|
+
moreTypes: true,
|
|
886
311
|
structuredClone: true,
|
|
887
312
|
});
|
|
888
313
|
var serialized = packr.pack(object);
|
|
@@ -1252,4 +677,4 @@
|
|
|
1252
677
|
});
|
|
1253
678
|
});
|
|
1254
679
|
|
|
1255
|
-
}(msgpackr, chai));
|
|
680
|
+
}(msgpackr, chai, fs));
|
package/node-index.js
CHANGED
|
@@ -16,7 +16,6 @@ function tryRequire(moduleId) {
|
|
|
16
16
|
let require = createRequire(import.meta.url)
|
|
17
17
|
return require(moduleId)
|
|
18
18
|
} catch (error) {
|
|
19
|
-
|
|
20
|
-
console.warn('For browser usage, directly use msgpackr/unpack or msgpackr/pack modules. ' + error.message.split('\n')[0])
|
|
19
|
+
// native module is optional
|
|
21
20
|
}
|
|
22
21
|
}
|